Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson's disease

Myung Sik Lee, Chulhyoung Lyoo, Ismo Ulmanen, Ann Christine Syvänen, Juha O Rinne

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

A single nucleotide polymorphism at the nucleotide 1947 in the catechol-O-methyltransferase (COMT) gene encodes the high and low activity forms of the enzyme. We investigated COMT genotypes of 73 Korean patients with Parkinson's disease (PD), 29 with multiple system atrophy (MSA), and 49 controls, and analyzed the response to levodopa challenge in the PD patients. We found no significant difference in the distribution of the COMT genotypes among the three groups. The frequencies of the G- and A-alleles in the total population were 75 and 25%, respectively. The levodopa response was determined by a single oral levodopa challenge test with Sinemet® (25/250 mg) in the patients with PD. The motor response evaluated by the time to peak response, the duration and magnitude of the response in the motor part of the Unified Parkinson's Disease Rating Scale; tapping or walking times showed no significant difference between the genotypes. Thus, pharmacokinetic or pharmacodynamic factors other than the investigated genetic variant of the COMT enzyme seem to determine the response to levodopa in PD.

Original languageEnglish
Pages (from-to)131-134
Number of pages4
JournalNeuroscience Letters
Volume298
Issue number2
DOIs
Publication statusPublished - 2001 Feb 2

Fingerprint

Catechol O-Methyltransferase
Levodopa
Parkinson Disease
Genotype
Multiple System Atrophy
Therapeutics
Enzymes
Walking
Single Nucleotide Polymorphism
Nucleotides
Pharmacokinetics
Alleles
Population
Genes

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)

Cite this

Lee, Myung Sik ; Lyoo, Chulhyoung ; Ulmanen, Ismo ; Syvänen, Ann Christine ; O Rinne, Juha. / Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson's disease. In: Neuroscience Letters. 2001 ; Vol. 298, No. 2. pp. 131-134.
@article{238890cecbd24446a0691925cc5a9224,
title = "Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson's disease",
abstract = "A single nucleotide polymorphism at the nucleotide 1947 in the catechol-O-methyltransferase (COMT) gene encodes the high and low activity forms of the enzyme. We investigated COMT genotypes of 73 Korean patients with Parkinson's disease (PD), 29 with multiple system atrophy (MSA), and 49 controls, and analyzed the response to levodopa challenge in the PD patients. We found no significant difference in the distribution of the COMT genotypes among the three groups. The frequencies of the G- and A-alleles in the total population were 75 and 25{\%}, respectively. The levodopa response was determined by a single oral levodopa challenge test with Sinemet{\circledR} (25/250 mg) in the patients with PD. The motor response evaluated by the time to peak response, the duration and magnitude of the response in the motor part of the Unified Parkinson's Disease Rating Scale; tapping or walking times showed no significant difference between the genotypes. Thus, pharmacokinetic or pharmacodynamic factors other than the investigated genetic variant of the COMT enzyme seem to determine the response to levodopa in PD.",
author = "Lee, {Myung Sik} and Chulhyoung Lyoo and Ismo Ulmanen and Syv{\"a}nen, {Ann Christine} and {O Rinne}, Juha",
year = "2001",
month = "2",
day = "2",
doi = "10.1016/S0304-3940(00)01749-3",
language = "English",
volume = "298",
pages = "131--134",
journal = "Neuroscience Letters",
issn = "0304-3940",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson's disease. / Lee, Myung Sik; Lyoo, Chulhyoung; Ulmanen, Ismo; Syvänen, Ann Christine; O Rinne, Juha.

In: Neuroscience Letters, Vol. 298, No. 2, 02.02.2001, p. 131-134.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson's disease

AU - Lee, Myung Sik

AU - Lyoo, Chulhyoung

AU - Ulmanen, Ismo

AU - Syvänen, Ann Christine

AU - O Rinne, Juha

PY - 2001/2/2

Y1 - 2001/2/2

N2 - A single nucleotide polymorphism at the nucleotide 1947 in the catechol-O-methyltransferase (COMT) gene encodes the high and low activity forms of the enzyme. We investigated COMT genotypes of 73 Korean patients with Parkinson's disease (PD), 29 with multiple system atrophy (MSA), and 49 controls, and analyzed the response to levodopa challenge in the PD patients. We found no significant difference in the distribution of the COMT genotypes among the three groups. The frequencies of the G- and A-alleles in the total population were 75 and 25%, respectively. The levodopa response was determined by a single oral levodopa challenge test with Sinemet® (25/250 mg) in the patients with PD. The motor response evaluated by the time to peak response, the duration and magnitude of the response in the motor part of the Unified Parkinson's Disease Rating Scale; tapping or walking times showed no significant difference between the genotypes. Thus, pharmacokinetic or pharmacodynamic factors other than the investigated genetic variant of the COMT enzyme seem to determine the response to levodopa in PD.

AB - A single nucleotide polymorphism at the nucleotide 1947 in the catechol-O-methyltransferase (COMT) gene encodes the high and low activity forms of the enzyme. We investigated COMT genotypes of 73 Korean patients with Parkinson's disease (PD), 29 with multiple system atrophy (MSA), and 49 controls, and analyzed the response to levodopa challenge in the PD patients. We found no significant difference in the distribution of the COMT genotypes among the three groups. The frequencies of the G- and A-alleles in the total population were 75 and 25%, respectively. The levodopa response was determined by a single oral levodopa challenge test with Sinemet® (25/250 mg) in the patients with PD. The motor response evaluated by the time to peak response, the duration and magnitude of the response in the motor part of the Unified Parkinson's Disease Rating Scale; tapping or walking times showed no significant difference between the genotypes. Thus, pharmacokinetic or pharmacodynamic factors other than the investigated genetic variant of the COMT enzyme seem to determine the response to levodopa in PD.

UR - http://www.scopus.com/inward/record.url?scp=0035793491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035793491&partnerID=8YFLogxK

U2 - 10.1016/S0304-3940(00)01749-3

DO - 10.1016/S0304-3940(00)01749-3

M3 - Article

C2 - 11163295

AN - SCOPUS:0035793491

VL - 298

SP - 131

EP - 134

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

IS - 2

ER -